Mutations in Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate
synthase (dhps) genes have been used as means to predict treatment failure to sulfadoxine …

Saharan Africa started showing resistance to this drug in late 1950s which was followed in
other parts of the World1-4. In India, the chloroquine resistance was first reported from …

Background Malaria is a major cause of infant morbidity and mortality in sub-Saharan Africa,
and is often complicated by severe anaemia. Resistance of Plasmodium falciparum to most …

Malawi changed its national policy for malaria treatment in 1993, becoming the first country
in Africa to replace chloroquine by sulfadoxine and pyrimethamine combination (SP) as the …

Prior to the 2001 malarial treatment policy change in Tanzania, we conducted trials to
assess the efficacy of sulfadoxine-pyrimethamine (SP) and the usefulness of molecular …

There is much discussion on how new drugs can be developed for use in developing
countries at a price that makes them accessible to those who need them most. The …

Abstract We studied (in 1998 and 1999) some factors that may be linked to the spread of
chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) resistance in 7 discrete communities …

OBJECTIVE: To evaluate the therapeutic efficacy of sulfadoxine-pyrimethamine,
amodiaquine, and the sulfadoxine-pyrimethamine-amodiaquine combination for the …

Introduction: The successes of HIV treatment scale-up and the availability of new prevention
tools have raised hopes that the epidemic can finally be controlled and ended. Reduction in …

Since 1993 sulphadoxine/pyrimethamine (SP) has been used as the first‐line drug for
uncomplicated Plasmodium falciparum malaria in Malawi. To investigate the current efficacy …